The Role of Plasminogen Receptors in Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (1 May 2023) | Viewed by 3563
Special Issue Editors
2. Department of Biochemistry & Molecular Biology, Dalhousie University, Halifax, NS B3H 4R2, Canada
Interests: role of the plasminogen system in disease; redox regulation by annexin proteins
Special Issue Information
Dear Colleagues,
Since the groundbreaking discovery by Fisher (1925) that avian tissue explants transformed to malignancy by viruses generate high levels of fibrinolytic activity under conditions in which cultures of normal cells do not, it has been clear that the plasminogen/plasmin system plays a fundamental role in tumor growth, invasion and metastasis. Although the plasminogen activators, tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), have been well characterized and their role in converting plasminogen to plasmin is well understood, it has been unclear how this process is regulated at the cell surface. The transformative studies of Plow, Miles, and Felez defined the pathway for regulating this process; the cell surface possesses specific binding sites for plasminogen, which is provided by a set of distinct cell-surface proteins called plasminogen receptors. The plasminogen receptors tightly regulate both the tPA- and uPA-dependent conversion of plasminogen to plasmin. Although at least twelve plasminogen receptors have been described, it is unclear which plasminogen receptors contribute to the enhanced fibrinolytic activity of cancer cells. The purpose of this Special Issue, entitled The Role of Plasminogen Receptors in Cancers, is to explore the expanding diversity of plasminogen receptors that participate in plasmin generation by cancer cells and how targeting these proteins in human cancer may provide new opportunities for personalized anti-cancer therapy. This Special Issue welcomes reviews and original research articles.
Dr. David Waisman
Dr. Alamelu Bharadwaj
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- plasminogen
- plasmin
- plasminogen receptors
- cancer
- oncogenesis
- proteases
- proteinases
- fibrinolysis
- metastasis
- invasion
